Three compounds, one proposed connection. NAD+ salvage, NNMT inhibition and MOTS-c signalling represent different parts of the metabolic picture. The theory behind combining them is that each compound could influence a separate but interconnected pathway involved in cellular energy production, metabolic regulation and mitochondrial function. But there is an important distinction between a mechanism that appears plausible in laboratory research and a combination that has been demonstrated to work safely and effectively. The proposed synergy between NAD+, 5-amino-1MQ and MOTS-c has not been established in human clinical trials. In this article, we will explore the biological rationale behind the combination, explain what each compound is being investigated for, and examine where the science supports the theory and where significant questions remain. This is a research and educational discussion, not medical advice. The mechanisms discussed below should not be interpreted as evidence that combining these compounds produces superior metabolic outcomes. 1. Understanding the Bigger Picture: Cellular Energy and Metabolism Every cell needs energy to maintain its structure, regulate biochemical reactions, repair damage and perform its specialised functions. Much of this energy is supplied through adenosine triphosphate (ATP), which is generated through several interconnected metabolic pathways. Three important concepts are relevant here: - NAD+ availability: Nicotinamide adenine dinucleotide participates in redox reactions that help transfer electrons during energy metabolism. - Nicotinamide metabolism: Cells recycle and process nicotinamide through several pathways, including pathways involved in maintaining NAD+ levels. - AMPK and mitochondrial signalling: Cellular signalling systems help coordinate energy production and consumption in response to changing metabolic conditions. These systems do not operate independently. Changes in one pathway can influence others, but the relationship is more complicated than simply increasing a supply molecule, blocking a competing pathway and stimulating mitochondrial activity.

Tesamorelin is one of the more interesting compounds in growth hormone research. As a synthetic growth hormone-releasing hormone (GHRH) analogue, it stimulates the body's own growth hormone (GH) secretion rather than supplying growth hormone directly. That mechanism makes tesamorelin particularly interesting to researchers investigating the GH and insulin-like growth factor 1 (IGF-1) axis. However, stimulating this pathway also creates potential risks that deserve careful consideration. Tesamorelin is not side-effect free, and increasing GH activity is not automatically beneficial. The most important safety considerations include fluid retention, joint and muscle discomfort, carpal tunnel-like symptoms, injection-site reactions, changes in blood glucose and elevated IGF-1. These risks are documented in the prescribing information for FDA-approved tesamorelin formulations. This article examines the known adverse effects, the underlying biology and the limitations of applying clinical evidence to investigational peptide research. 1. What Makes Tesamorelin Different? Tesamorelin is a synthetic analogue of GHRH, a signalling hormone that stimulates the pituitary gland to release GH. GH subsequently influences multiple physiological processes, including the production of IGF-1, a hormone and growth factor involved in growth, metabolism and tissue function. This pathway can be simplified as follows: - GHRH signalling: Tesamorelin activates GHRH receptors in the pituitary. - GH secretion: The pituitary releases growth hormone. - IGF-1 production: GH stimulates IGF-1 production, particularly in the liver. - Downstream effects: GH and IGF-1 influence metabolism, body composition and other biological processes. Tesamorelin is therefore a GH-releasing agent, not a direct GH replacement product. Its clinical evidence also needs to be understood in context. In the United States, FDA-approved tesamorelin formulations are indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. They are not approved as general weight-loss treatments, anti-ageing therapies or bodybuilding agents.

A New Direction in Bone Health Research Osteoporosis remains a major public health challenge worldwide. As bone density declines and the internal structure of bone deteriorates, the risk of fractures increases, sometimes following a relatively minor fall or impact. According to the International Osteoporosis Foundation, approximately one in three women and one in five men over the age of 50 will experience an osteoporosis related fracture during their remaining lifetime. These injuries can have lasting consequences for mobility, independence and quality of life. International Osteoporosis Foundation Much of the current osteoporosis treatment landscape focuses on slowing bone breakdown. However, another approach involves stimulating the biological processes responsible for forming new bone. This is the area being explored by Entera Bio, a biotechnology company developing oral peptide and protein replacement medicines. Its experimental candidate, EB613, is an oral formulation of parathyroid hormone fragment PTH(1-34), also known as teriparatide. The goal is to deliver a bone building signal through a tablet rather than an injection. In October 2026, Entera presented additional analyses from its Phase 2 research at the American Society for Bone and Mineral Research annual meeting, highlighting findings in postmenopausal women with osteoporosis. The company is preparing a Phase 3 programme, with initiation planned for late 2026 and initial results anticipated in the second half of 2028. These remain development milestones rather than evidence that the treatment is approved or proven to prevent fractures. Entera Bio, October 2026 The central question is whether EB613 can translate promising changes in bone mineral density into a safe, effective and clinically meaningful treatment.

Retatrutide has become one of the most talked-about investigational medicines in the peptide and metabolic-health space. Its clinical trial results have attracted considerable attention, particularly after reports of substantial weight loss in people with obesity. Yet there is a major difference between an investigational medicine being studied in clinical trials and a product being legally available for routine pharmacy compounding. The question is straightforward: if researchers have already produced and studied retatrutide, why can’t a legitimate compounding pharmacy simply make it? The answer comes down to regulatory eligibility, pharmaceutical quality systems, and the distinction between regulated drug manufacturing and products sold outside the authorised pharmaceutical supply chain. First, an Important Update About Retatrutide Older discussions sometimes describe retatrutide as an early-stage investigational drug that has not yet reached Phase 3. That is no longer accurate. As of October 2026, Eli Lilly has reported positive results from multiple pivotal Phase 3 trials, including TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3. These studies have investigated retatrutide in people with obesity or overweight and different weight-related health conditions. In TRIUMPH-1, participants receiving the highest studied dose lost an average of 28.3% of their body weight over 80 weeks, according to Lilly’s reported results. In TRIUMPH-2, which enrolled participants with obesity or overweight and type 2 diabetes, the highest-dose group lost an average of 20.8% over 80 weeks. These are substantial findings. However, they are results from specific clinical trials, not a guarantee of the same outcome for every individual. Lilly announced that it planned to submit a Biologics License Application to the US Food and Drug Administration (FDA) in the first quarter of 2027. As of the date of this article, retatrutide remains investigational and is not FDA-approved for routine public use.

New research presented at the 2026 American Society of Clinical Oncology meeting has raised an intriguing question: could GLP-1 medications do more than regulate blood sugar and support weight loss? GLP-1 medications have become some of the most talked-about drugs in modern medicine. Medicines such as Ozempic and Wegovy, which contain semaglutide, and other drugs that act on the GLP-1 pathway have transformed the treatment of type 2 diabetes and obesity. But researchers are now investigating another potential effect: whether these medications might be associated with a lower risk of certain cancers progressing to metastatic disease. In 2026, research highlighted by the American Society of Clinical Oncology (ASCO) reported that people with certain early-stage cancers who were taking GLP-1 receptor agonists were less likely to progress to stage IV disease than comparable patients taking another class of diabetes medication. The differences were substantial for lung, breast, colorectal and liver cancers. The findings have attracted attention from researchers and science communicators, including physician and author Dr William Li, who has discussed the broader relationship between GLP-1 biology, blood vessels, metabolism and cancer. However, there is a crucial distinction between an encouraging research finding and proof that a medication prevents cancer from spreading. The study found an association, not proof that GLP-1 drugs directly stop metastasis. Understanding that distinction is essential when interpreting the headlines. In this article, we will examine the research, the percentages behind the headlines, the possible biological explanations, and what the findings mean for people interested in cancer prevention, metabolic health and the body's natural GLP-1 system. 1. The 2026 ASCO Study: What Did Researchers Find? The study presented at the 2026 ASCO Annual Meeting examined real-world health records from approximately 12,000 people with seven types of cancer. Participants had stage I, II or III disease and were compared according to whether they received a GLP-1 receptor agonist or a DPP-4 inhibitor, another class of medication used to manage type 2 diabetes.